Evidence map›Paper›PMID 28086979›Full record

Trial reportJournal of translational medicine2017

B cell repertoires in HLA-sensitized kidney transplant candidates undergoing desensitization therapy.

John F Beausang, H Christina Fan, Rene Sit, Maria U Hutchins, Kshama Jirage, Rachael Curtis, Edward Hutchins, Stephen R Quake, Julie M Yabu

Abstract readClinical Trial
In one paragraph

Trial report in Journal of translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. IVIg-induced plasmablasts in patients with Guillain-Barré syndrome.Annals of clinical and translational neurology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

John F BeausangCareDx, 3260 Bayshore Blvd, Brisbane, CA, 94005, USA.
H Christina FanImmumetrix, LLC, 3183 Porter Drive, Palo Alto, CA, 94304, USA.
Rene SitCareDx, 3260 Bayshore Blvd, Brisbane, CA, 94005, USA.
Maria U HutchinsImmumetrix, LLC, 3183 Porter Drive, Palo Alto, CA, 94304, USA.
Kshama JirageImmumetrix, LLC, 3183 Porter Drive, Palo Alto, CA, 94304, USA.
Rachael CurtisImmumetrix, LLC, 3183 Porter Drive, Palo Alto, CA, 94304, USA.
Edward HutchinsImmumetrix, LLC, 3183 Porter Drive, Palo Alto, CA, 94304, USA.
Stephen R QuakeDepartment of Bioengineering, Stanford University, 318 Campus Drive, Stanford, CA, 94305, USA.
Julie M YabuDepartment of Medicine, Stanford University School of Medicine, 750 Welch Road, Palo Alto, CA, 94304, USA. jyabu@berkeley.edu.

Funding

Improving Kidney Transplant Outcomes Using Novel B-cell Immune ProfilingK23AI104401 · NIAID · STANFORD UNIVERSITY · PI YABU, JULIE M · 2012 to 2015
$528k
NIAID NIH HHS K23 AI104401
6 · The paper itself

Abstract

backgroundKidney transplantation is the most effective treatment for end-stage renal disease. Sensitization refers to pre-existing antibodies against human leukocyte antigen (HLA) protein and remains a major barrier to successful transplantation. Despite implementation of desensitization strategies, many candidates fail to respond. Our objective was to determine whether measuring B cell repertoires could differentiate candidates that respond to desensitization therapy.

methodsWe developed an assay based on high-throughput DNA sequencing of the variable domain of the heavy chain of immunoglobulin genes to measure changes in B cell repertoires in 19 highly HLA-sensitized kidney transplant candidates undergoing desensitization and 7 controls with low to moderate HLA sensitization levels. Responders to desensitization had a decrease of 5% points or greater in cumulated calculated panel reactive antibody (cPRA) levels, and non-responders had no decrease in cPRA.

resultsDominant B cell clones were not observed in highly sensitized candidates, suggesting that the B cells responsible for sensitization are either not present in peripheral blood or present at comparable levels to other circulating B cells. Candidates that responded to desensitization therapy had pre-treatment repertoires composed of a larger fraction of class-switched (IgG and IgA) isotypes compared to non-responding candidates. After B cell depleting therapy, the proportion of switched isotypes increased and the mutation frequencies of the remaining non-switched isotypes (IgM and IgD) increased in both responders and non-responders, perhaps representing a shift in the repertoire towards memory B cells or plasmablasts. Conversely, after transplantation, non-switched isotypes with fewer mutations increased, suggesting a shift in the repertoire towards naïve B cells.

conclusionsRelative abundance of different B cell isotypes is strongly perturbed by desensitization therapy and transplantation, potentially reflecting changes in the relative abundance of memory and naïve B cell compartments. Candidates that responded to therapy experienced similar changes to those that did not respond. Further studies are required to understand differences between these two groups of highly sensitized kidney transplant candidates.

Indexed as

Desensitization, ImmunologicKidney TransplantationAdultB-LymphocytesFemaleHLA AntigensHumansImmunoglobulins, IntravenousMaleMiddle AgedRituximabHLA AntigensImmunoglobulins, IntravenousRituximabB cellsDesensitizationDNA sequencingHLA sensitizationImmune repertoireKidney transplantation

Identifiers

PMID28086979
PMCPMC5237299

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.